We agree that it is very important to examine whether screening programs for depression, anxiety, and increased risk of suicide accurately identify children and adolescents with those conditions, as well as whether screening leads to improved health outcomes among children and adolescents. We agree that it is equally important to assess the potential harms of screening and treatment. There are, however, three points that we suggest should be re-examined in the draft research plan.
Read More »Tag: anxiety
How to Cope with Coronavirus Anxiety
Anxiety can be scary, but it is possible to overcome it. If you are feeling like you are spinning out of control with anxiety reading the news about the coronavirus, this article can help.
Read More »NCHR Testimony on Singulair and Neuropsychiatric Side Effects
September 27, 2019. Singulair has serious side effects and we need much better data to determine the likely benefit and risk of harm for patients. FDA has an important role to play in encouraging this research. In the meantime, patients, parents, and clinicians must be given clear information about the risks so that they can make an informed decision about whether to use montelukast (Singulair).
Read More »Do Anti-Anxiety Medications Cause Dementia?
Exercise was shown to protect against the brain shrinking even if people with a family history of Alzheimer’s disease.
Read More »Statement of NCHR At the April 8, 2009 FDA Psychopharmacologic Drugs Advisory Committee Meeting Regarding Seroquel XR
April 8, 2009. We testified arguing that Seroquel, an Antipsychotic medication, should be kept off the market as it has not been conclusively proven that it does not increase the risk of diabetes or tardive dyskinesia.
Read More »